MedTrace Logo

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2018-07-05

Study results available
· View outcomes & findings →

Summary

Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).

Conditions

  • Ovulation Suppression

Interventions

DRUG

levonorgestrel and ethinyl estradiol

pregnancy prevention

Sponsors & Collaborators

  • Agile Therapeutics

    lead INDUSTRY

Principal Investigators

  • Elizabeth Garner, MD, MPH · Agile Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250210 on ClinicalTrials.gov